Currently established immune-oncology biomarkers like the tumor mutational burden or PDL1 expression30 may give insight into neo-antigenicity or a preexisting immune response but are expensive and remain uninformative regarding the quantity and spatial distribution of tumor-infiltrating CD8+ T cells, one of the key prerequisites for successful response to immunotherapy. The gene discussed is CD8A; the disease is neoplasm.